05-28-2009: The German Federal Ministry of Education and Research will fund a clinical research project for the early detection of colorectal cancer, to be realized by an alliance of Scientists from the 2nd Medical Clinic of the University vHospital rechts der Isar at the Munich Technical University, the Association of Statutory Health Insurance Physicians in Bavaria (KVB) and Epigenomics AG. The total project budget is expected to sum up to around EUR 1.3 million. The project aims at developing a novel blood test that, in addition to colorectal cancer, can also detect pre-malignant precursors of the disease, so called adenomas and polyps.
Compared to the currently recommended colonoscopy such an approach would be much more convenient for individuals undergoing colorectal cancer screening. A non-invasive blood test could thus complement currently available conventional prevention strategies including colonoscopy and thereby might significantly contribute to reducing mortality from colorectal cancer.
Characteristic features in tumor development are inheritable modifications in gene regulation and gene expression, so called epigenetic changes. As these changes occur in the earliest stages of colorectal cancer development, they are ideally suited as diagnostic markers. Based on such an epigenetic marker, the DNA methylation marker mSEPT9, Epigenomics AG has already developed a blood test which can reliably detect colorectal cancer in the stages I to IV of disease progression.
The purpose of the current research project is to assess the suitability of the mSEPT9 test for the blood-based early detection of polyps and, if appropriate, to further optimize it for broader application, for example by combining the mSEPT9 marker with one or more additional markers.
The alliance represents a novel form of collaboration which combines partners from industry, academia and public health care providers to work on innovative aspects in preventive oncology.
Epigenomics AG announced the publication of a study authored by Professor Matthias Ebert at University of Heidelberg entitled “TFAP2E-DKK4 and Chemoresistance in Colorectal Cancer” in The New England Journal of Medicine.In this study involving more than 200 patients in four independent coho ... more
Epigenomics AG announced the appointment of Noel Doheny as the new Chief Executive Officer (CEO) of its subsidiary Epigenomics Inc. in Seattle, WA, USA, reporting to Geert Nygaard, CEO of Epigenomics AG. Mr. Doheny will start in his new position in early May 2011.
Mr. Doheny has 30+ years o ... more
Epigenomics AG and NextPharma Technologies announced that the companies have signed a global manufacturing contract for Epigenomics' Epi proColon product. Epi proColon, currently marketed in Europe, is the world's first in-vitro diagnostic test for the detection of colorectal cancer in a s ... more
A special group of proteins, the so-called chaperones, helps other proteins to obtain their correct conformation. Until now scientists supposed that hydrolyzing ATP provides the energy for the large conformational changes of chaperone Hsp90. Now a research team from the Nanosystems Initiati ... more
For a long time miniaturization has been the magic word in electronics. Dr. Willi Auwaerter and Professor Johannes Barth, together with their team of physicists at the Technische Universitaet Muenchen (TUM), have now presented a novel molecular switch in the journal Nature Nanotechnology. D ... more
The mouth-watering aroma of roasted cocoa beans — key ingredient for chocolate — emerges from substances that individually smell like potato chips, cooked meat, peaches, raw beef fat, cooked cabbage, human sweat, earth, cucumber, honey and an improbable palate of other distinctly un-cocoa-l ... more